You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDoxepin
Accession NumberDB01142  (APRD00398)
TypeSmall Molecule
GroupsApproved
DescriptionDoxepin hydrochloride is a dibenzoxepin-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, doxepin does not affect mood or arousal, but may cause sedation. In depressed individuals, doxepin exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as doxepin and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Doxepin has less sedative and anticholinergic effects than amitriptyline. See toxicity section below for a complete listing of side effects. Doxepin may be used to treat depression and insomnia. Unlabeled indications include chronic and neuropathic pain, and anxiety. Doxepin may also be used as a second line agent to treat idiopathic urticaria.
Structure
Thumb
Synonyms
Cidoxepin
Doxepin
Sinequan
Zonalon
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-doxepin - Cap 10mgcapsule10 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-doxepin-cap 25mgcapsule25 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-doxepin-cap 50mgcapsule50 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada
Alti-doxepin-cap 75mgcapsule75 mgoralAltimed Pharma Inc.1995-12-312005-05-27Canada
Doxepin Hydrochloridecream50 mg/gtopicalRenaissance Pharma, Inc.2016-03-07Not applicableUs
Doxepine-10 - Capcapsule10 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Doxepine-100 - Capcapsule100 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Doxepine-150 - Capcapsule150 mgoralPro Doc Limitee1995-12-312009-07-23Canada
Doxepine-25 -capcapsule25 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Doxepine-50 - Capcapsule50 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Doxepine-75 - Capcapsule75 mgoralPro Doc Limitee1995-12-312010-07-13Canada
Novo-doxepincapsule100 mgoralTeva Canada Limited1992-12-31Not applicableCanada
Novo-doxepincapsule25 mgoralTeva Canada Limited1992-12-31Not applicableCanada
Novo-doxepincapsule150 mgoralTeva Canada Limited1992-12-31Not applicableCanada
Novo-doxepincapsule50 mgoralTeva Canada Limited1992-12-31Not applicableCanada
Novo-doxepincapsule75 mgoralTeva Canada Limited1992-12-31Not applicableCanada
Ntp-doxepincapsule75 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-doxepincapsule100 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-doxepincapsule25 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-doxepincapsule50 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Prudoxincream50 mg/gtopicalSmith & Nephew, Inc.2012-12-212015-11-30Us
Prudoxincream50 mg/gtopicalPrestium Pharma, Inc.2015-06-01Not applicableUs
Prudoxincream50 mg/gtopicalHEALTHPOINT, LTD2001-10-012015-11-30Us
Rho-doxepin - Cap 25mgcapsule25 mgoralRhodiapharm Inc1995-12-311998-08-05Canada
Rho-doxepin - Cap 50mgcapsule50 mgoralRhodiapharm Inc1995-12-311998-08-05Canada
Rho-doxepin-10 Mg Capcapsule10 mgoralRhodiapharm Inc1995-12-311998-08-05Canada
Silenortablet3 mg/1oralPernix Therapeutics, LLC2010-08-01Not applicableUs
Silenortablet6 mg/1oralPernix Therapeutics, LLC2010-08-01Not applicableUs
Silenortablet3.00 mgoralPaladin Labs Inc2013-01-08Not applicableCanada
Silenortablet6.00 mgoralPaladin Labs Inc2013-01-08Not applicableCanada
Sinequan Cap 100mgcapsule100 mgoralErfa Canada 2012 Inc1975-12-312015-06-05Canada
Sinequan Cap 10mgcapsule10 mgoralErfa Canada 2012 Inc1970-12-31Not applicableCanada
Sinequan Cap 150mgcapsule150 mgoralPfizer Canada Inc1983-12-312000-07-26Canada
Sinequan Cap 25mgcapsule25 mgoralErfa Canada 2012 Inc1970-12-31Not applicableCanada
Sinequan Cap 50mgcapsule50 mgoralErfa Canada 2012 Inc1970-12-31Not applicableCanada
Sinequan Cap 75mgcapsule75 mgoralErfa Canada 2012 Inc1977-12-312015-06-05Canada
Triadapin Cap 100mgcapsule100 mgoralAventis Pharma Inc1985-12-312002-07-29Canada
Triadapin Cap 10mgcapsule10 mgoralAventis Pharma Inc1985-12-312001-07-20Canada
Triadapin Cap 25mgcapsule25 mgoralAventis Pharma Inc1985-12-312001-07-20Canada
Triadapin Cap 50mgcapsule50 mgoralAventis Pharma Inc1985-12-312002-07-29Canada
Triadapin Cap 75mgcapsule75 mgoralAventis Pharma Inc1985-12-312002-07-29Canada
Zonaloncream50 mg/gtopicalPharma Derm A Division Of Fougera Pharmaceuticals Inc.1994-04-01Not applicableUs
Zonaloncream50 mg/gtopicalLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-30Not applicableUs
Zonaloncream50 mg/gtopicalPrestium Pharma, Inc.2015-03-12Not applicableUs
Zonalon Cream 5%cream5 %topicalValeant Canada Lp/valeant Canada s.e.c.1995-12-312016-07-08Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-doxepincapsule10 mgoralApotex Inc1993-12-31Not applicableCanada
Apo-doxepincapsule150 mgoralApotex Inc1993-12-31Not applicableCanada
Apo-doxepincapsule25 mgoralApotex Inc1993-12-31Not applicableCanada
Apo-doxepincapsule50 mgoralApotex Inc1993-12-31Not applicableCanada
Apo-doxepincapsule100 mgoralApotex Inc1993-12-31Not applicableCanada
Apo-doxepincapsule75 mgoralApotex Inc1993-12-31Not applicableCanada
Doxepin Hydrochloridecapsule50 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralREMEDYREPACK INC.2012-01-17Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralSTAT Rx USA LLC2011-05-04Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralPhysicians Total Care, Inc.1995-01-03Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralH.J. Harkins Company, Inc.2011-05-04Not applicableUs
Doxepin Hydrochloridecapsule150 mg/1oralREMEDYREPACK INC.2015-08-03Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Doxepin Hydrochloridesolution, concentrate10 mg/mLoralTeva Pharmaceuticals USA Inc1987-11-06Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralREMEDYREPACK INC.2010-12-17Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralMylan Institutional Inc.1998-10-01Not applicableUs
Doxepin Hydrochloridecapsule75 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralPhysicians Total Care, Inc.1996-04-24Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralbryant ranch prepack2012-10-18Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2010-12-07Not applicableUs
Doxepin Hydrochloridecapsule100 mg/1oralSTAT Rx USA LLC2011-05-04Not applicableUs
Doxepin Hydrochloridecapsule75 mg/1oralPhysicians Total Care, Inc.2003-06-10Not applicableUs
Doxepin Hydrochloridecapsule75 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs
Doxepin Hydrochloridecapsule150 mg/1oralPar Pharmaceutical Inc1987-11-09Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralAidarex Pharmaceuticals LLC2012-10-18Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Doxepin Hydrochloridesolution10 mg/mLoralCarilion Materials Management1998-12-29Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralMedsource Pharmaceuticals1986-05-13Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs
Doxepin Hydrochloridecapsule75 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralMylan Institutional Inc.1998-10-01Not applicableUs
Doxepin Hydrochloridecapsule100 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralPhysicians Total Care, Inc.1999-09-28Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralbryant ranch prepack2012-10-18Not applicableUs
Doxepin Hydrochloridecapsule100 mg/1oralREMEDYREPACK INC.2010-12-23Not applicableUs
Doxepin Hydrochloridecapsule10 mg/1oralRebel Distributors Corp1986-05-13Not applicableUs
Doxepin Hydrochloridecapsule150 mg/1oralPhysicians Total Care, Inc.2007-08-01Not applicableUs
Doxepin Hydrochloridecapsule100 mg/1oralContract Pharmacy Services Pa2010-04-06Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-05Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralA S Medication Solutions Llc2012-10-18Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralDIRECT RX2014-01-01Not applicableUs
Doxepin Hydrochloridecapsule100 mg/1oralMedsource Pharmaceuticals1986-05-13Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralMylan Institutional Inc.1998-10-01Not applicableUs
Doxepin Hydrochloridecapsule150 mg/1oralAv Kare, Inc.2012-08-31Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2010-12-23Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralSTAT Rx USA LLC2011-05-04Not applicableUs
Doxepin Hydrochloridecapsule100 mg/1oralPhysicians Total Care, Inc.1996-10-03Not applicableUs
Doxepin Hydrochloridecapsule75 mg/1oralTYA Pharmaceuticals1986-05-13Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralRebel Distributors Corp1986-05-13Not applicableUs
Doxepin Hydrochloridecapsule25 mg/1oralCardinal Health2011-08-18Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralUnit Dose Services2011-05-04Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralMylan Pharmaceuticals Inc.1986-05-13Not applicableUs
Doxepin Hydrochloridesolution10 mg/mLoralSilarx Pharmaceuticals, Inc1998-12-29Not applicableUs
Doxepin Hydrochloridecapsule50 mg/1oralbryant ranch prepack2011-05-04Not applicableUs
Doxepin Hydrochloridecapsule75 mg/1oralREMEDYREPACK INC.2010-12-02Not applicableUs
Doxepin Hydrochloridecapsule100 mg/1oralMylan Institutional Inc.1998-10-01Not applicableUs
Doxepin Hydrochloridecapsule150 mg/1oralSTAT Rx USA LLC1987-11-09Not applicableUs
Doxepin Hydrochloridesolution10 mg/mLoralMorton Grove Pharmaceuticals, Inc.1995-02-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdapinPennwaIt
AponalPfizer
CuratinNot Available
DoxepineShou Chan
QuitaxonLexphar
SinequanPfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Doxepin Hydrochloride
Thumb
  • InChI Key: MHNSPTUQQIYJOT-UHFFFAOYSA-N
  • Monoisotopic Mass: 315.138992038
  • Average Mass: 315.837
DBSALT000059
Categories
UNII5ASJ6HUZ7D
CAS number1668-19-5
WeightAverage: 279.3761
Monoisotopic: 279.162314299
Chemical FormulaC19H21NO
InChI KeyInChIKey=ODQWQRRAPPTVAG-BOPFTXTBSA-N
InChI
InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11-
IUPAC Name
dimethyl(3-{9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
SMILES
[H]C(CCN(C)C)=C1C2=CC=CC=C2COC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxepines
Sub ClassDibenzoxepines
Direct ParentDibenzoxepines
Alternative Parents
Substituents
  • Dibenzoxepine
  • Alkyl aryl ether
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationDoxepin is used for the treatment of depression and/or anxiety. It can also be used for chronic urticaria and in the management of pain.
PharmacodynamicsDoxepin, a tricyclic antidepressant of the dibenzoxepin type, is used to treat depression and anxiety and, topically, pruritus associated with eczema. Doxepin has substantial anticholinergic and sedative effects. The E (trans)-isomer is more active as a serotonin reuptake inhibitor while the Z-isomer acts as a sedative.
Mechanism of actionThe mechanism of action of doxepin is not completely understood. It is thought that like amitriptyline, doxepin enhances the actions of norepinephrine and serotonin by blocking their reuptake at the neuronal membrane. However, doxepin weakly inhibits the reuptake of dopamine. Doxepin may also act on histamine H1-receptors, resulting in sedative effects, and β-adrenergic receptors. It is also an antagonist of 5-hydroxytryptamine (serotonin) receptors, alpha-1 adrenergic receptor, and muscarinic cholinergic receptors.
Related Articles
AbsorptionWell-absorbed from the GI tract. Peak plasma concentrations occur within 2 hours of oral administration.
Volume of distributionNot Available
Protein bindingDoxepin and desmethyldoxepin is 80% protein bound. It is also a lipophillic drug and is capable of crossing the blood-brain-barrier.
Metabolism

Extensively metabolized in the liver via the same pathways as other TCAs. N-demethylation produces an active metabolite, N-desmethyldoxepin. CYP2D6 specifically hydroxylates the E-isomer.

SubstrateEnzymesProduct
Doxepin
N-desmethyldoxepinDetails
Doxepin
Not Available
Doxepin N-oxideDetails
Doxepin
Not Available
(E)-2-hydroxydoxepinDetails
Doxepin
(Z)-N-desmethyldoxepinDetails
Doxepin
(E)-N-desmethyldoxepinDetails
Doxepin
Not Available
Doxepin-N-oxideDetails
Doxepin
Not Available
(E)-2-O-glucuronyldoxepinDetails
N-desmethyldoxepin
Not Available
Didesmethyl doxepinDetails
Doxepin N-oxide
Not Available
Doxepin N-oxide glucuronideDetails
(E)-2-hydroxydoxepin
Not Available
Hydroxydoxepin glucuronideDetails
N-desmethyldoxepin
Hydroxydesmethyl doxepinDetails
(E)-2-hydroxydoxepin
Not Available
Hydroxydesmethyl doxepinDetails
Hydroxydesmethyl doxepin
Not Available
Hydroxydesmethyl doxepin glucuronideDetails
Route of eliminationNot Available
Half life6 - 24.5 hours
ClearanceNot Available
ToxicityLD50=26 (mg/kg) (in mice, iv); LD50=16 (mg/kg) (in rats, iv); Cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Doxepin Metabolism PathwayDrug metabolismSMP00641
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9931
Blood Brain Barrier+0.9381
Caco-2 permeable+0.8108
P-glycoprotein substrateSubstrate0.8147
P-glycoprotein inhibitor IInhibitor0.8147
P-glycoprotein inhibitor IIInhibitor0.8214
Renal organic cation transporterInhibitor0.7883
CYP450 2C9 substrateNon-substrate0.7846
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7475
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.917
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6362
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8322
BiodegradationNot ready biodegradable0.8461
Rat acute toxicity3.2478 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5346
hERG inhibition (predictor II)Inhibitor0.6959
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg
Capsuleoral10 mg/1
Capsuleoral100 mg/1
Capsuleoral150 mg/1
Capsuleoral25 mg/1
Capsuleoral50 mg/1
Capsuleoral75 mg/1
Solutionoral10 mg/mL
Solution, concentrateoral10 mg/mL
Capsuleoral100 mg
Capsuleoral150 mg
Capsuleoral25 mg
Capsuleoral50 mg
Capsuleoral75 mg
Tabletoral3 mg/1
Tabletoral3.00 mg
Tabletoral6 mg/1
Tabletoral6.00 mg
Creamtopical50 mg/g
Creamtopical5 %
Prices
Unit descriptionCostUnit
Zonalon 5% Cream 45 gm Tube190.13USD tube
Zonalon 5% Cream 30 gm Tube144.29USD tube
Doxepin hcl powder8.88USD g
Doxepin 150 mg capsule3.33USD capsule
Prudoxin 5% cream3.05USD g
Sinequan 100 mg Capsule1.22USD capsule
Novo-Doxepin 150 mg Capsule1.18USD capsule
Sinequan 75 mg Capsule0.93USD capsule
Zonalon 5% cream0.89USD g
Doxepin HCl 150 mg capsule0.87USD capsule
Apo-Doxepin 100 mg Capsule0.68USD capsule
Novo-Doxepin 100 mg Capsule0.68USD capsule
Sinequan 50 mg Capsule0.64USD capsule
Doxepin 50 mg capsule0.57USD capsule
Doxepin HCl 100 mg capsule0.56USD capsule
Novo-Doxepin 75 mg Capsule0.52USD capsule
Apo-Doxepin 75 mg Capsule0.52USD capsule
Doxepin HCl 75 mg capsule0.43USD capsule
Apo-Doxepin 50 mg Capsule0.36USD capsule
Novo-Doxepin 50 mg Capsule0.36USD capsule
Sinequan 25 mg Capsule0.35USD capsule
Doxepin 10 mg capsule0.32USD capsule
Sinequan 10 mg Capsule0.28USD capsule
Doxepin HCl 50 mg capsule0.25USD capsule
Doxepin HCl 25 mg capsule0.23USD capsule
Doxepin 75 mg capsule0.21USD capsule
Doxepin HCl 10 mg capsule0.21USD capsule
Apo-Doxepin 10 mg Capsule0.2USD capsule
Apo-Doxepin 25 mg Capsule0.19USD capsule
Novo-Doxepin 25 mg Capsule0.19USD capsule
Doxepin 25 mg capsule0.18USD capsule
Doxepin 100 mg capsule0.14USD capsule
Doxepin HCl 10 mg/ml Concentrate0.13USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6211229 No2000-02-172020-02-17Us
US7915307 No2007-08-242027-08-24Us
US8513299 No2010-04-142030-04-14Us
US9107898 No2008-05-012028-05-01Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point265 °C at 2.00E-01 mm HgPhysProp
water solubility31.6 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.29SANGSTER (1994)
logS-3.4ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0319 mg/mLALOGPS
logP4.08ALOGPS
logP3.84ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity98.24 m3·mol-1ChemAxon
Polarizability32.47 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Luigi Schioppi, Brian Talmadge Dorsey, Michael Skinner, John Carter, Robert Mansbach, Philip Jochelson, Roberta L. Rogowski, Cara Casseday, Meredith Perry, Bryan Knox, “LOW-DOSE DOXEPIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME.” U.S. Patent US20090074862, issued March 19, 2009.

US20090074862
General References
  1. Virtanen R, Iisalo E, Irjala K: Protein binding of doxepin and desmethyldoxepin. Acta Pharmacol Toxicol (Copenh). 1982 Aug;51(2):159-64. [PubMed:7113722 ]
  2. Virtanen R, Scheinin M, Iisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):371-6. [PubMed:7293791 ]
  3. Negro-Alvarez JM, Carreno-Rojo A, Funes-Vera E, Garcia-Canovas A, Abellan-Aleman AF, Rubio del Barrio R: Pharmacologic therapy for urticaria. Allergol Immunopathol (Madr). 1997 Jan-Feb;25(1):36-51. [PubMed:9111875 ]
  4. Sansone RA, Sansone LA: Pain, pain, go away: antidepressants and pain management. Psychiatry (Edgmont). 2008 Dec;5(12):16-9. [PubMed:19724772 ]
  5. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109 ]
External Links
ATC CodesN06AA12
AHFS Codes
  • 28:16.04.28
  • 84:08.00
PDB EntriesNot Available
FDA labelDownload (588 KB)
MSDSDownload (73.4 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Doxepin can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Doxepin can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Doxepin.
3,4-MethylenedioxyamphetamineDoxepin may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Doxepin.
3,4-MethylenedioxymethamphetamineDoxepin may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Doxepin can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Doxepin.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Doxepin.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Doxepin.
AbirateroneThe serum concentration of Doxepin can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Doxepin.
AcenocoumarolDoxepin may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Doxepin.
AcetophenazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Doxepin.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Doxepin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Doxepin.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Doxepin.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Doxepin.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Doxepin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Doxepin.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Doxepin.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Doxepin.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Doxepin.
AlogliptinThe serum concentration of Doxepin can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Doxepin can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Doxepin.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Doxepin.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Doxepin.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Doxepin.
AmiodaroneDoxepin may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Doxepin can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Doxepin is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Doxepin.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Doxepin.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Doxepin.
AmoxapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Doxepin is combined with Amperozide.
AmphetamineAmphetamine may decrease the sedative activities of Doxepin.
AmphetamineDoxepin may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Doxepin can be increased when it is combined with Amprenavir.
AnagrelideDoxepin may increase the QTc-prolonging activities of Anagrelide.
Antithrombin III humanThe serum concentration of Doxepin can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Doxepin can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Doxepin.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Doxepin.
AprepitantThe serum concentration of Doxepin can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Doxepin can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Doxepin is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Arformoterol.
ArgatrobanThe serum concentration of Doxepin can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Doxepin is combined with Aripiprazole.
ArmodafinilThe metabolism of Doxepin can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Doxepin.
ArtemetherDoxepin may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Doxepin can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Doxepin.
AsenapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Asenapine.
AsunaprevirThe serum concentration of Doxepin can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Doxepin can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Doxepin.
AtomoxetineThe metabolism of Doxepin can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Doxepin.
AzaperoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Azaperone.
AzelastineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Doxepin.
AzithromycinDoxepin may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Doxepin can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Doxepin.
BambuterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Doxepin.
BatimastatThe serum concentration of Doxepin can be increased when it is combined with Batimastat.
BedaquilineDoxepin may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilThe serum concentration of Doxepin can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the serotonergic activities of Doxepin.
BenzamidineThe serum concentration of Doxepin can be increased when it is combined with Benzamidine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Doxepin.
BenzphetamineBenzphetamine may decrease the sedative activities of Doxepin.
BenzphetamineDoxepin may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Doxepin.
Benzylpenicilloyl PolylysineDoxepin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Doxepin.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Doxepin.
BetaxololThe metabolism of Doxepin can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Doxepin.
BexaroteneThe serum concentration of Doxepin can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Doxepin is combined with Bifeprunox.
BivalirudinThe serum concentration of Doxepin can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Doxepin can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Doxepin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Doxepin can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Doxepin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxepin.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Doxepin is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Doxepin.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Doxepin.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Doxepin.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Doxepin.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Doxepin.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Doxepin.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Doxepin.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Doxepin.
BupropionThe metabolism of Doxepin can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Doxepin.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Doxepin.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Doxepin.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Doxepin.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Doxepin.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Doxepin.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Doxepin.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Doxepin.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Doxepin.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Doxepin.
CaffeineThe metabolism of Doxepin can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Doxepin.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Doxepin.
CandoxatrilThe serum concentration of Doxepin can be increased when it is combined with Candoxatril.
CapecitabineThe metabolism of Doxepin can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Doxepin can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Doxepin can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Doxepin.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Doxepin.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Doxepin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Doxepin.
CariprazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Doxepin.
CaroxazoneCaroxazone may increase the serotonergic activities of Doxepin.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Doxepin.
CefpodoximeDoxepin can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
CefuroximeDoxepin can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
CelecoxibThe metabolism of Doxepin can be decreased when combined with Celecoxib.
CeliprololThe risk or severity of adverse effects can be increased when Doxepin is combined with Celiprolol.
CeritinibThe serum concentration of Doxepin can be increased when it is combined with Ceritinib.
CeritinibDoxepin may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Doxepin.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Doxepin.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Doxepin.
ChloramphenicolThe metabolism of Doxepin can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Doxepin.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Doxepin.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Doxepin.
ChloroquineDoxepin may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Doxepin can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Doxepin.
ChlorphentermineChlorphentermine may decrease the sedative activities of Doxepin.
ChlorphentermineDoxepin may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Doxepin can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Doxepin is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Doxepin.
CholecalciferolThe metabolism of Doxepin can be decreased when combined with Cholecalciferol.
ChymostatinThe serum concentration of Doxepin can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Doxepin can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Doxepin can be increased when it is combined with Cilazapril.
CimetidineThe metabolism of Doxepin can be decreased when combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Doxepin.
CinacalcetThe serum concentration of Doxepin can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Doxepin.
CiprofloxacinDoxepin may increase the QTc-prolonging activities of Ciprofloxacin.
CirazolineDoxepin may increase the vasopressor activities of Cirazoline.
CisaprideDoxepin may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Doxepin.
CitalopramThe risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.
CitalopramThe metabolism of Doxepin can be decreased when combined with Citalopram.
ClarithromycinDoxepin may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Doxepin can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Doxepin can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Doxepin is combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Clenbuterol.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Doxepin.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Doxepin.
ClobazamThe metabolism of Doxepin can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Doxepin.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Doxepin.
ClomipramineThe risk or severity of adverse effects can be increased when Doxepin is combined with Clomipramine.
ClomipramineThe metabolism of Doxepin can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Doxepin.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Doxepin.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Doxepin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Doxepin.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Doxepin.
ClotrimazoleThe metabolism of Doxepin can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Clozapine.
ClozapineThe metabolism of Doxepin can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Doxepin can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Doxepin.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Doxepin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Doxepin.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Doxepin.
ConivaptanThe serum concentration of Doxepin can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Doxepin.
CrizotinibDoxepin may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Doxepin can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Doxepin is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxepin.
CyclosporineThe metabolism of Doxepin can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Doxepin.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Doxepin.
Cyproterone acetateThe serum concentration of Doxepin can be decreased when it is combined with Cyproterone acetate.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Doxepin.
Dabigatran etexilateThe serum concentration of Doxepin can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Doxepin.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Doxepin.
DantroleneThe risk or severity of adverse effects can be increased when Doxepin is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Doxepin.
DapiprazoleThe risk or severity of adverse effects can be increased when Doxepin is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Doxepin.
DarifenacinThe metabolism of Doxepin can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Doxepin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Doxepin can be increased when it is combined with Dasatinib.
DasatinibDoxepin can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Doxepin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Doxepin.
DeferasiroxThe serum concentration of Doxepin can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Doxepin.
DelavirdineThe metabolism of Doxepin can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Doxepin.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Doxepin.
DesipramineThe metabolism of Doxepin can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Doxepin is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Doxepin.
DesmopressinThe risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Doxepin is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Doxepin.
DexamethasoneThe serum concentration of Doxepin can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Doxepin.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxepin.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Doxepin.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Doxepin.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Doxepin.
DexmethylphenidateDoxepin can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Doxepin.
DextroamphetamineDoxepin may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Doxepin.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Doxepin.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Doxepin.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Doxepin.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Doxepin.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Doxepin.
DicoumarolDoxepin may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Doxepin.
DifenoxinThe risk or severity of adverse effects can be increased when Doxepin is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Doxepin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Doxepin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Doxepin.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Doxepin.
DihydroergotamineThe metabolism of Doxepin can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Doxepin.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Doxepin.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Doxepin.
DiltiazemThe metabolism of Doxepin can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Doxepin.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxepin.
DiphenhydramineThe metabolism of Doxepin can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Doxepin is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Doxepin.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Doxepin.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Doxepin.
DisopyramideDoxepin may increase the QTc-prolonging activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Doxepin is combined with Dobutamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Doxepin.
DofetilideDoxepin may increase the QTc-prolonging activities of Dofetilide.
DolasetronDoxepin may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Doxepin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Doxepin.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Doxepin.
DoxycyclineThe metabolism of Doxepin can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DoxylamineThe risk or severity of adverse effects can be increased when Doxepin is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Doxepin.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
DronedaroneThe metabolism of Doxepin can be decreased when combined with Dronedarone.
DronedaroneDoxepin may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Doxepin is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Doxepin.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Doxepin.
DuloxetineThe metabolism of Doxepin can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Doxepin is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Doxepin.
EcabetThe serum concentration of Doxepin can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Doxepin.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Doxepin.
EdoxabanThe serum concentration of Doxepin can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Doxepin can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Doxepin is combined with Efavirenz.
ElafinThe serum concentration of Doxepin can be increased when it is combined with Elafin.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Doxepin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Doxepin.
EliglustatDoxepin may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Doxepin can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Doxepin can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Doxepin can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Doxepin can be increased when it is combined with Enalkiren.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Doxepin.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Doxepin.
EnzalutamideThe serum concentration of Doxepin can be decreased when it is combined with Enzalutamide.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Doxepin.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Doxepin.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Doxepin.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Doxepin.
ErgonovineThe risk or severity of adverse effects can be increased when Doxepin is combined with Ergonovine.
ErgotamineDoxepin may increase the vasopressor activities of Ergotamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Doxepin.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Doxepin.
ErythromycinDoxepin may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Doxepin can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Doxepin is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Doxepin can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Doxepin can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Doxepin.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Doxepin.
EstriolThe serum concentration of Estriol can be increased when it is combined with Doxepin.
EstroneThe serum concentration of Estrone can be increased when it is combined with Doxepin.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Doxepin.
EthanolDoxepin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Doxepin.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Doxepin.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Doxepin.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Doxepin.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Doxepin.
Ethyl biscoumacetateDoxepin may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Doxepin.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Doxepin.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Doxepin.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Doxepin.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Doxepin.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Doxepin.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Doxepin.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Doxepin.
EtoperidoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Doxepin.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Doxepin.
EtravirineThe serum concentration of Doxepin can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Doxepin.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Doxepin.
EzogabineThe risk or severity of adverse effects can be increased when Doxepin is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Doxepin.
FencamfamineThe risk or severity of adverse effects can be increased when Doxepin is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Doxepin is combined with Fenfluramine.
FenoterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Fenoterol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Doxepin.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxepin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Doxepin.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Doxepin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Doxepin.
FlecainideDoxepin may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Doxepin is combined with Flibanserin.
FloxuridineThe metabolism of Doxepin can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Doxepin can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Doxepin.
FlunarizineThe risk or severity of adverse effects can be increased when Doxepin is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Doxepin.
FluorouracilThe metabolism of Doxepin can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluoxetine.
FluoxetineThe metabolism of Doxepin can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Doxepin is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Doxepin.
FluspirileneThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Doxepin.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Doxepin.
FluvastatinThe metabolism of Doxepin can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Doxepin is combined with Fluvoxamine.
FluvoxamineThe metabolism of Doxepin can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Formoterol.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Doxepin.
FosamprenavirThe serum concentration of Doxepin can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Doxepin can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Doxepin can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Doxepin is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Doxepin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Doxepin.
FurazolidoneFurazolidone may increase the serotonergic activities of Doxepin.
Fusidic AcidThe serum concentration of Doxepin can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Doxepin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Doxepin is combined with gabapentin enacarbil.
Gadobenic acidDoxepin may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Doxepin.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Doxepin.
GeldanamycinThe serum concentration of Doxepin can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Doxepin.
GemfibrozilThe metabolism of Doxepin can be decreased when combined with Gemfibrozil.
GemifloxacinDoxepin may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Doxepin.
GM6001The serum concentration of Doxepin can be increased when it is combined with GM6001.
GoserelinDoxepin may increase the QTc-prolonging activities of Goserelin.
GranisetronDoxepin may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Doxepin.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Doxepin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Doxepin.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Doxepin.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Doxepin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Doxepin.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Doxepin.
HaloperidolThe risk or severity of adverse effects can be increased when Doxepin is combined with Haloperidol.
HaloperidolThe metabolism of Doxepin can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Doxepin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Doxepin.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Doxepin.
HirulogThe serum concentration of Doxepin can be increased when it is combined with Hirulog.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxepin.
HydracarbazineHydracarbazine may increase the serotonergic activities of Doxepin.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Doxepin.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Doxepin.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Doxepin.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Doxepin.
Hydroxyamphetamine hydrobromideDoxepin may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
HydroxyzineThe risk or severity of adverse effects can be increased when Doxepin is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Doxepin.
IbutilideDoxepin may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Doxepin can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Iloperidone.
ImatinibThe metabolism of Doxepin can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Doxepin.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Doxepin.
ImipramineThe metabolism of Doxepin can be decreased when combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Doxepin is combined with Indalpine.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Doxepin.
IndinavirThe serum concentration of Doxepin can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Doxepin.
IproclozideIproclozide may increase the serotonergic activities of Doxepin.
IproniazidIproniazid may increase the serotonergic activities of Doxepin.
IrbesartanThe metabolism of Doxepin can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Doxepin.
IsavuconazoniumThe metabolism of Doxepin can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Doxepin.
IsocarboxazidThe risk or severity of adverse effects can be increased when Doxepin is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Doxepin is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Doxepin.
IsoflurophateThe serum concentration of Doxepin can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Doxepin can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Doxepin is combined with Isoprenaline.
IsradipineThe metabolism of Doxepin can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Doxepin.
ItraconazoleThe metabolism of Doxepin can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Doxepin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Doxepin.
IxazomibThe serum concentration of Doxepin can be increased when it is combined with Ixazomib.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Doxepin.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Doxepin.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Doxepin.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Doxepin.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Doxepin.
KetoconazoleThe metabolism of Doxepin can be decreased when combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Doxepin.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Doxepin.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Doxepin.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Doxepin.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Doxepin.
LeflunomideThe metabolism of Doxepin can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Doxepin.
LenvatinibDoxepin may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Doxepin can be increased when it is combined with Lepirudin.
LeuprolideDoxepin may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Doxepin.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Doxepin.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Doxepin.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Doxepin.
LevocetirizineThe risk or severity of adverse effects can be increased when Doxepin is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Doxepin is combined with Levodopa.
LevofloxacinDoxepin may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Doxepin.
LevomilnacipranThe risk or severity of adverse effects can be increased when Doxepin is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Doxepin.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Doxepin.
LidocaineThe metabolism of Doxepin can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Doxepin is combined with Lidocaine.
LinagliptinThe serum concentration of Doxepin can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Doxepin.
LinezolidThe risk or severity of adverse effects can be increased when Doxepin is combined with Linezolid.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Doxepin.
LiotrixLiotrix may increase the arrhythmogenic activities of Doxepin.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Doxepin.
LisdexamfetamineDoxepin may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Doxepin can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Doxepin is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Doxepin.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Doxepin.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Doxepin.
LopinavirThe serum concentration of Doxepin can be increased when it is combined with Lopinavir.
LopinavirDoxepin may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Doxepin.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Doxepin.
LorcaserinThe metabolism of Doxepin can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Doxepin is combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Doxepin.
LosartanThe metabolism of Doxepin can be decreased when combined with Losartan.
LovastatinThe metabolism of Doxepin can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Doxepin is combined with Lu AA21004.
LuliconazoleThe serum concentration of Doxepin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Doxepin can be decreased when it is combined with Lumacaftor.
LumefantrineDoxepin may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Doxepin can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Doxepin is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Doxepin.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Doxepin.
MebanazineMebanazine may increase the serotonergic activities of Doxepin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Doxepin.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Doxepin.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Doxepin.
MelperoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Melperone.
MephentermineMephentermine may decrease the sedative activities of Doxepin.
MephentermineDoxepin may increase the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Doxepin.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Doxepin.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Doxepin.
MesoridazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Mesoridazine.
MetaraminolDoxepin may increase the vasopressor activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Doxepin.
MethadoneDoxepin may increase the QTc-prolonging activities of Methadone.
MethadoneThe metabolism of Doxepin can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Doxepin.
MethamphetamineMethamphetamine may decrease the sedative activities of Doxepin.
MethamphetamineDoxepin may increase the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Doxepin.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Doxepin.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Doxepin.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Doxepin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Doxepin.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Methotrimeprazine.
MethoxamineDoxepin may increase the vasopressor activities of Methoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Doxepin.
MethsuximideThe risk or severity of adverse effects can be increased when Doxepin is combined with Methsuximide.
Methylene blueDoxepin may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Doxepin.
MethylphenidateDoxepin can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Doxepin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Doxepin.
MetoclopramideThe risk or severity of adverse effects can be increased when Doxepin is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Doxepin.
MetoprololThe metabolism of Doxepin can be decreased when combined with Metoprolol.
MetyrosineDoxepin may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Doxepin.
MexiletineThe metabolism of Doxepin can be decreased when combined with Mexiletine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Doxepin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Doxepin.
MidodrineDoxepin may increase the vasopressor activities of Midodrine.
MifepristoneThe metabolism of Doxepin can be decreased when combined with Mifepristone.
MifepristoneDoxepin may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Doxepin is combined with Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Doxepin.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Doxepin.
MirabegronThe metabolism of Doxepin can be decreased when combined with Mirabegron.
MirtazapineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Doxepin.
MitotaneThe serum concentration of Doxepin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Doxepin.
MoclobemideMoclobemide may increase the serotonergic activities of Doxepin.
MoclobemideThe risk or severity of adverse effects can be increased when Doxepin is combined with Moclobemide.
ModafinilThe serum concentration of Doxepin can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Doxepin can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Doxepin.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Doxepin.
MoxifloxacinDoxepin may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Doxepin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxepin.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Doxepin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
NabiloneThe risk or severity of adverse effects can be increased when Doxepin is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Doxepin.
NafcillinThe serum concentration of Doxepin can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Doxepin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Doxepin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Doxepin.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Doxepin.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Doxepin.
NCX 4016The serum concentration of Doxepin can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Doxepin can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Doxepin.
NelfinavirThe serum concentration of Doxepin can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Doxepin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Doxepin can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Doxepin.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Doxepin.
NicardipineThe metabolism of Doxepin can be decreased when combined with Nicardipine.
NicorandilDoxepin may increase the hypotensive activities of Nicorandil.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Doxepin.
NilotinibThe metabolism of Doxepin can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Doxepin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Doxepin.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Doxepin.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Doxepin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Doxepin.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Doxepin.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Doxepin.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Doxepin.
OctamoxinOctamoxin may increase the serotonergic activities of Doxepin.
OfloxacinDoxepin may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Olanzapine.
OlaparibThe metabolism of Doxepin can be decreased when combined with Olaparib.
OlodaterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Doxepin.
OmapatrilatThe serum concentration of Doxepin can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Doxepin.
OmeprazoleThe metabolism of Doxepin can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Doxepin is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Doxepin.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Doxepin.
OrciprenalineThe risk or severity of adverse effects can be increased when Doxepin is combined with Orciprenaline.
OrphenadrineDoxepin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Doxepin.
OsanetantThe risk or severity of adverse effects can be increased when Doxepin is combined with Osanetant.
OsimertinibThe serum concentration of Doxepin can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Doxepin can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Doxepin.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Doxepin.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Doxepin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Doxepin.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Doxepin.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Doxepin.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Doxepin.
PalbociclibThe serum concentration of Doxepin can be increased when it is combined with Palbociclib.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Doxepin.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Doxepin.
PalonosetronPalonosetron may increase the serotonergic activities of Doxepin.
PanobinostatDoxepin may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Doxepin can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Doxepin can be decreased when combined with Pantoprazole.
ParaldehydeDoxepin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Doxepin.
PargylinePargyline may increase the serotonergic activities of Doxepin.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Doxepin.
Peginterferon alfa-2bThe serum concentration of Doxepin can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineDoxepin may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Doxepin.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Doxepin.
PerampanelThe risk or severity of adverse effects can be increased when Doxepin is combined with Perampanel.
PerflutrenDoxepin may increase the QTc-prolonging activities of Perflutren.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Doxepin.
PerindoprilThe serum concentration of Doxepin can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Doxepin is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Doxepin.
PhenelzinePhenelzine may increase the serotonergic activities of Doxepin.
PhenelzineThe risk or severity of adverse effects can be increased when Doxepin is combined with Phenelzine.
PhenindioneDoxepin may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Doxepin.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Doxepin.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Doxepin.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Doxepin.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Doxepin.
PhenprocoumonDoxepin may increase the anticoagulant activities of Phenprocoumon.
PhenterminePhentermine may decrease the sedative activities of Doxepin.
PhentermineDoxepin may increase the stimulatory activities of Phentermine.
PhenylephrineDoxepin may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Doxepin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Doxepin.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Doxepin.
PhosphoramidonThe serum concentration of Doxepin can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Doxepin is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Pirbuterol.
PirlindolePirlindole may increase the serotonergic activities of Doxepin.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Doxepin.
PivhydrazinePivhydrazine may increase the serotonergic activities of Doxepin.
PizotifenThe risk or severity of adverse effects can be increased when Doxepin is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Doxepin.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Doxepin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Doxepin.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Doxepin.
PosaconazoleThe metabolism of Doxepin can be decreased when combined with Posaconazole.
PramipexoleDoxepin may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Doxepin.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Doxepin.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Doxepin.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Doxepin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Doxepin.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Doxepin.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Doxepin.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Doxepin.
PrimaquineDoxepin may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Doxepin.
PrinomastatThe serum concentration of Doxepin can be increased when it is combined with Prinomastat.
ProcainamideDoxepin may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Doxepin.
ProcarbazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Doxepin.
PromazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Promazine.
PromazineThe metabolism of Doxepin can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Doxepin.
PropafenoneDoxepin may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Doxepin.
PropericiazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Doxepin.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Doxepin.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Doxepin.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Doxepin.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Doxepin.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Doxepin.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Doxepin.
PyrimethamineThe metabolism of Doxepin can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Doxepin.
QuetiapineThe risk or severity of adverse effects can be increased when Doxepin is combined with Quetiapine.
QuinaprilThe serum concentration of Doxepin can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Doxepin.
QuinidineThe metabolism of Doxepin can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Doxepin.
QuinineThe metabolism of Doxepin can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Doxepin.
RamiprilThe serum concentration of Doxepin can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Doxepin.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Doxepin.
RanolazineThe metabolism of Doxepin can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Doxepin.
RasagilineThe risk or severity of adverse effects can be increased when Doxepin is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doxepin.
RemikirenThe serum concentration of Doxepin can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Doxepin is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Doxepin is combined with Reserpine.
RifabutinThe metabolism of Doxepin can be increased when combined with Rifabutin.
RifampicinThe metabolism of Doxepin can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Doxepin.
RifapentineThe metabolism of Doxepin can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Doxepin.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Doxepin.
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Doxepin.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Doxepin.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Doxepin.
RitodrineThe risk or severity of adverse effects can be increased when Doxepin is combined with Ritodrine.
RitonavirThe serum concentration of Doxepin can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Doxepin can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Doxepin.
RolapitantThe metabolism of Doxepin can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Doxepin.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Doxepin.
RopiniroleDoxepin may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Doxepin can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Doxepin.
RotigotineDoxepin may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Doxepin.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Doxepin.
SafrazineSafrazine may increase the serotonergic activities of Doxepin.
SalbutamolThe risk or severity of adverse effects can be increased when Doxepin is combined with Salbutamol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Doxepin.
SalmeterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Salmeterol.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Doxepin.
SaxagliptinThe serum concentration of Doxepin can be increased when it is combined with Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxepin.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Doxepin.
SelegilineSelegiline may increase the serotonergic activities of Doxepin.
SelegilineThe risk or severity of adverse effects can be increased when Doxepin is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Doxepin.
SertindoleThe risk or severity of adverse effects can be increased when Doxepin is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Doxepin is combined with Sertraline.
SertralineThe metabolism of Doxepin can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Doxepin.
SildenafilThe metabolism of Doxepin can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Doxepin.
SiltuximabThe serum concentration of Doxepin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Doxepin can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Doxepin can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Doxepin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Doxepin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Doxepin.
SorafenibThe metabolism of Doxepin can be decreased when combined with Sorafenib.
SotalolDoxepin may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Doxepin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Doxepin.
SpiraprilThe serum concentration of Doxepin can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Doxepin can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe risk or severity of adverse effects can be increased when Doxepin is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doxepin.
SulfadiazineThe metabolism of Doxepin can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Doxepin can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleDoxepin may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Doxepin can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Doxepin is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Doxepin.
SuvorexantThe risk or severity of adverse effects can be increased when Doxepin is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Doxepin.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Doxepin.
TapentadolThe risk or severity of adverse effects can be increased when Doxepin is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Doxepin is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Doxepin.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Doxepin.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Doxepin.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Doxepin is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Doxepin can be increased when it is combined with Telaprevir.
TelavancinDoxepin may increase the QTc-prolonging activities of Telavancin.
TelithromycinDoxepin may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Doxepin can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Doxepin.
TemocaprilThe serum concentration of Doxepin can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Doxepin.
TenofovirThe metabolism of Doxepin can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Doxepin can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Doxepin is combined with Terbutaline.
TeriflunomideThe serum concentration of Doxepin can be decreased when it is combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Doxepin.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Doxepin.
ThalidomideDoxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Doxepin.
TheophyllineThe metabolism of Doxepin can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Doxepin.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Doxepin.
ThioproperazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Doxepin.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Doxepin.
ThiorphanThe serum concentration of Doxepin can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Doxepin is combined with Thiothixene.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Doxepin.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Doxepin.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Doxepin.
TicagrelorThe metabolism of Doxepin can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Doxepin can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Doxepin.
TimololThe serum concentration of Timolol can be increased when it is combined with Doxepin.
TipranavirThe serum concentration of Doxepin can be increased when it is combined with Tipranavir.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Doxepin.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Doxepin.
TocilizumabThe serum concentration of Doxepin can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Doxepin can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Doxepin.
ToloxatoneToloxatone may increase the serotonergic activities of Doxepin.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Doxepin.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Doxepin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Doxepin.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Doxepin.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Doxepin.
TrandolaprilThe serum concentration of Doxepin can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Doxepin.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Doxepin is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Doxepin.
TranylcypromineThe risk or severity of adverse effects can be increased when Doxepin is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Doxepin.
TrazodoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Doxepin.
TrifluoperazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Doxepin is combined with Triflupromazine.
TrimethoprimThe metabolism of Doxepin can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Doxepin.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Doxepin.
UbenimexThe serum concentration of Doxepin can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Doxepin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Doxepin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Doxepin.
ValsartanThe metabolism of Doxepin can be decreased when combined with Valsartan.
VandetanibDoxepin may increase the QTc-prolonging activities of Vandetanib.
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Doxepin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Doxepin.
VemurafenibThe serum concentration of Doxepin can be increased when it is combined with Vemurafenib.
VemurafenibDoxepin may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Doxepin can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Doxepin.
VerapamilThe metabolism of Doxepin can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Doxepin.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Doxepin.
VilanterolThe risk or severity of adverse effects can be increased when Doxepin is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Vilazodone.
VildagliptinThe serum concentration of Doxepin can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Doxepin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Doxepin.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Doxepin.
VoriconazoleThe metabolism of Doxepin can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Doxepin is combined with Vortioxetine.
WarfarinDoxepin may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Doxepin can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Doxepin.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Doxepin.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Doxepin.
ZafirlukastThe metabolism of Doxepin can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Doxepin.
ZiconotideThe risk or severity of adverse effects can be increased when Doxepin is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Doxepin.
ZimelidineThe risk or severity of adverse effects can be increased when Doxepin is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Doxepin is combined with Ziprasidone.
ZiprasidoneThe metabolism of Doxepin can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Doxepin.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Doxepin.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Doxepin.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Doxepin.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Doxepin.
ZotepineThe risk or severity of adverse effects can be increased when Doxepin is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Doxepin is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St.John's Wort.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K: Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 2004 Aug;44(8):890-900. [PubMed:15286093 ]
  2. Tran VT, Lebovitz R, Toll L, Snyder SH: [3H]doxepin interactions with histamine H1-receptors and other sites in guinea pig and rat brain homogenates. Eur J Pharmacol. 1981 Apr 9;70(4):501-9. [PubMed:7238574 ]
  3. Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, Iwata R, Tashiro M, Mochizuki H, Funaki Y, Kato M, Hongo M, Yanai K: Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci. 2004 Aug;20(3):803-10. [PubMed:15255990 ]
  4. Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96. [PubMed:3011460 ]
  5. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
  6. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  7. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941 ]
  8. Singh H, Becker PM: Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305. [PubMed:17685877 ]
  9. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000 ]
  10. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Beil W, Hannemann H, Sewing KF: Interaction of antidepressants and neuroleptics with histamine stimulated parietal cell adenylate cyclase and H+ secretion. Pharmacology. 1988;36(3):198-203. [PubMed:2897127 ]
  2. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. [PubMed:309138 ]
  3. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. [PubMed:309138 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. [PubMed:309138 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941 ]
  3. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499 ]
  4. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499 ]
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499 ]
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499 ]
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Ehlert FJ, Delen FM, Yun SH, Liem HA: The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther. 1990 Apr;253(1):13-9. [PubMed:2329499 ]
  3. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147-58. [PubMed:2141000 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941 ]
  3. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941 ]
  3. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38. [PubMed:19179941 ]
  3. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Maj J, Gancarczyk L, Gorszczyk L, Rawlow A: Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol. 1977 Dec;10(6):318-24. [PubMed:309138 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ, Leaney JL, Witchel HJ, Hancox JC: Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol. 2007 Aug 1;74(3):425-37. Epub 2007 May 3. [PubMed:17560554 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Szewczuk-Boguslawska M, Kiejna A, Beszlej JA, Orzechowska-Juzwenko K, Milejski P: Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4. [PubMed:15520506 ]
  2. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML: Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004 Jul;60(5):329-36. Epub 2004 May 28. [PubMed:15168101 ]
  3. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109 ]
  4. Haritos VS, Ghabrial H, Ahokas JT, Ching MS: Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000 Oct;10(7):591-603. [PubMed:11037801 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109 ]
  2. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. [PubMed:12180536 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109 ]
  2. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. [PubMed:12180536 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. [PubMed:12180536 ]
  2. Haritos VS, Ghabrial H, Ahokas JT, Ching MS: Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000 Oct;10(7):591-603. [PubMed:11037801 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. [PubMed:12180536 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:13